ArticleCardio-oncology (London, England)2026
Addition of malignancy into the CHADS2/CHA2DS2VASc score: better prediction of stroke risk in individuals with cancer and atrial fibrillation.
Article in Cardio-oncology (London, England), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeThe CHADS₂ and CHA₂DS₂VASc scoring systems guide thromboprophylaxis in atrial fibrillation (AF), but their performance is limited in patients with cancer. This study evaluated whether malignancy functions as an independent risk factor for ischemic stroke among patients with AF.
methodsUsing the TriNetX research network, we identified patients with AF with and without malignancy between 2015 and 2022, excluding those with prior cerebrovascular disease. Propensity score matching for CHA₂DS₂VASc variables and anticoagulation yielded two cohorts of 234,428 patients each. The primary outcome was ischemic stroke; secondary outcomes included major bleeding and all-cause mortality. Outcomes were assessed at 3 months, 6 months, 1 year, and 5 years following the index event.
resultsAt 3 months, stroke incidence was significantly higher among patients with AF and malignancy compared with AF alone (OR 2.092; CI 1.990-2.200). This increased risk persisted at 6 months (OR 1.978), 1 year (OR 1.795), and 5 years (OR 1.585). Mortality and major bleeding rates were also consistently higher in the AF and malignancy cohort across all time intervals.
conclusionPatients with AF and malignancy demonstrated a significantly higher risk of ischemic stroke despite matching for established CHA₂DS₂VASc risk factors, supporting malignancy as a potential independent contributor to stroke risk. Mortality and major bleeding were likewise higher, reflecting the combined burden of malignancy and AF. The relative odds of ischemic stroke exceeded those of major bleeding across all time points. Future studies should evaluate whether incorporating malignancy into the CHA₂DS₂VASc score improves stroke risk stratification in this population.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.